Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 65 of 105. Open to participants first (1,909), then studies with results posted, then the rest; newest registration first within each.

• The Absorption, Metabolism and Excretion of [14C]D-0316 in HumanStatus unknownNCT04464551Phase 1
• Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's MacroglobulinemiaCompletedNCT04463953Phase 2
• Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid TumoursCompletedNCT04462952Phase 1
• Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIbCompletedNCT04462445Phase 2
• Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System LymphomaActive, not recruitingNCT04462328Phase 1
• A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain MetastasesWithdrawnNCT04460729Phase 2
• Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast CancerTerminatedNCT04460430Phase 2
• Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04460248Phase 2
• Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung AdenocarcinomaStatus unknownNCT04459078Phase 2
• Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT04458610Phase 2
• Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)CompletedNCT04458051Phase 3
• T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialActive, not recruitingNCT04457596Phase 3
• A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor SubjectsCompletedNCT04457180Phase 1
• A Phase I Study of SHR1459 in Healthy SubjectsCompletedNCT04455100Phase 1
• A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver FunctionStatus unknownNCT04454762Phase 2
• A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）Status unknownNCT04453930Phase 2
• Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.Status unknownNCT04453423Phase 2
• Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast CancerStatus unknownNCT04452370Phase 2
• Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal CancerTerminatedNCT04450836Phase 2
• Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular LymphomaActive, not recruitingNCT04450173Phase 2
• A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of MeforminCompletedNCT04448821Phase 1
• A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPSStatus unknownNCT04447274Phase 2
• Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based ChemotherapyCompletedNCT04447118Phase 3
• LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)Active, not recruitingNCT04446962Phase 1/2
• Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic LeukemiaStatus unknownNCT04446806Phase 4
• A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)Active, not recruitingNCT04446650Phase 1/2
• Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial CarcinomaStatus unknownNCT04444193Not applicable
• Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCCStatus unknownNCT04443309Phase 1/2
• ADME Study of [14C]ICP-022 in Healthy MalesCompletedNCT04441450Not applicable
• Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell CarcinomaStatus unknownNCT04440917Phase 2
• A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom MacroglobulinemiaCompletedNCT04440059Phase 2
• A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung CancerStatus unknownNCT04439890Phase 3
• Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)WithdrawnNCT04439305Phase 2
• Ibrutinib for the Treatment of COVID-19 in Patients Requiring HospitalizationCompletedNCT04439006Phase 1
• Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib TreatmentTerminatedNCT04438902Phase 2
• A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSLStatus unknownNCT04438044Phase 2
• A Study of ICP-022 in Patients With R/R DLBCLCompletedNCT04438005Phase 2
• Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male SubjectsCompletedNCT04436562Phase 1
• Efficacy and Safety of Cabozantinib in Patients With Hepatocellular CarcinomaStatus unknownNCT04435977Phase 2
• The Absorption, Metabolism and Excretion of [14C]CM082 in HumanCompletedNCT04434326Phase 1
• Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot StudyCompletedNCT04431895Early Phase 1
• A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NETStatus unknownNCT04427787Phase 2
• A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid TumorTerminatedNCT04427774Phase 1
• Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)Active, not recruitingNCT04427293Phase 1
• Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung CancerStatus unknownNCT04425681Phase 2
• Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver TransplantStatus unknownNCT04425226Not applicable
• Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLCStatus unknownNCT04425135Phase 2
• A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated DiseaseStatus unknownNCT04424056Phase 3
• The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced PneumoniaStatus unknownNCT04422678Phase 3
• A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With CancerCompletedNCT04419623Phase 1
• Positioning Imatinib for Pulmonary Arterial HypertensionActive, not recruitingNCT04416750Phase 2
• Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway InhibitorCompletedNCT04416516Phase 2
• The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic CarcinomaStatus unknownNCT04415385Phase 2
• X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesStatus unknownNCT04415320Phase 2
• A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal FunctionStatus unknownNCT04414852Phase 1
• Ruxolitinib in the Treatment of Covid-19Status unknownNCT04414098Phase 2
• AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLCActive, not recruitingNCT04413201Phase 4
• Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCActive, not recruitingNCT04413123Phase 2
• Cabozantinib in High Grade Neuroendocrine NeoplasmsActive, not recruitingNCT04412629Phase 2
• A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant TumorStatus unknownNCT04412564Phase 2
• Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care TherapyWithdrawnNCT04412252Phase 2
• Afatinib in Advanced NRG1-Rearranged MalignanciesCompletedNCT04410653Phase 2
• A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult ParticipantsCompletedNCT04410094Phase 1
• A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male ParticipantsCompletedNCT04410081Phase 1
• Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of ImatinibTerminatedNCT04409223Phase 3
• A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 TabletsStatus unknownNCT04408079Phase 1
• Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast CancerStatus unknownNCT04407988Phase 2
• PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release FormulationCompletedNCT04403776Phase 1
• COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19CompletedNCT04403243Phase 2
• A Bioequivalence Study of Famitinib Malate on Healthy Chinese VolunteersCompletedNCT04400123Phase 1
• Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic TrialStatus unknownNCT04399798Phase 2
• A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung CancerStatus unknownNCT04398940Phase 2
• Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerActive, not recruitingNCT04398914Phase 2
• The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaActive, not recruitingNCT04398459Phase 2
• Low Dose Ruxolitinib in Combination With MethylprednisoloneCompletedNCT04397367Phase 1/2
• An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.Active, not recruitingNCT04395989Phase 2
• A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion GeneActive, not recruitingNCT04395677Phase 2
• A Bioavailability Study of SHR1459 on Healthy Chinese VolunteersCompletedNCT04395053Phase 1
• Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell CancerCompletedNCT04394975Phase 3
• Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell CarcinomaCompletedNCT04393506Phase 1
• Baricitinib Compared to Standard Therapy in Patients With COVID-19Status unknownNCT04393051Phase 2
• Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC PatientsStatus unknownNCT04390984Phase 1
• Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.CompletedNCT04390776Phase 1
• mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)Status unknownNCT04390464Phase 4
• TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial PneumoniaStatus unknownNCT04390061Phase 2
• Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell CarcinomaStatus unknownNCT04385654Phase 2
• A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction AdenocarcinomaStatus unknownNCT04385550Phase 3
• Peritransplant Ruxolitinib for Patients With Primary and Secondary MyelofibrosisActive, not recruitingNCT04384692Phase 2
• Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian CancerStatus unknownNCT04383977Phase 2
• A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal CancerStatus unknownNCT04380012Phase 2
• Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04376073Phase 2
• Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALLStatus unknownNCT04375683Phase 3
• Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19TerminatedNCT04373044Phase 2
• A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy SubjectsCompletedNCT04372407Phase 1
• A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy SubjectsCompletedNCT04372394Phase 1
• Lenvatinib Combined Toripalimab in Advanced Hepatocellular CarcinomaStatus unknownNCT04368078Phase 2
• Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast CancerCompletedNCT04367090Phase 1
• First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLCStatus unknownNCT04363255Phase 2
• Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal CancerCompletedNCT04362839Phase 1

← Tyrosine Kinase Inhibitors overview